A Phase I Trial of A-CAR032 in Participants With mCRPC

Recruiting now · Phase 1

Conditions studied: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

In brief

This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.

Key facts

Study ID

NCT07344311

Run by

Shanghai AbelZeta Ltd.

People needed

27

Starts

2026-01-13

Expected to finish

2042-01-31

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be 18 years or older at the time of signing the ICF. Type of Participant and Disease Characteristics
• Participants with:
• A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.
• Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone analogue. Participants receiving medical castration therapy with gonadotropin-releasing hormone analogues should continue this treatment during the study.
• Measurable PSA≥1 ng/mL AND
• Evidence of progression within 6 months prior to screening
• Participant has previously received an ARPI (ie, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide) whether before or in the metastatic castration-resistant setting, and in the judgment of the investigator, be ineligible for standard treatment.
• Minimum life expectancy of > 12 weeks prior to apheresis in the opinion of the investigator.
• Adequate organ and marrow function
• Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment biopsies.
• Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• The participant voluntarily participates in the study, and the individual or their legal guardian signs the ICF.

You may not qualify if…

• Known life-threatening allergies, hypersensitivity, or intolerance to the CAR-T product or its excipients, including dimethyl sulfoxide (DMSO).
• Contraindication to lymphodepleting agents, including fludarabine and/or cyclophosphamide.
• History of another primary malignancy except for:
• Malignancy treated with curative intent and with no known active disease within 3 years before the apheresis and of low potential risk for recurrence.
• Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease.
• Adequately treated carcinoma in situ without evidence of disease.
• Participants with known brain metastases.
• History of splenectomy or organ transplantation.
• Prior treatment with:
• Any CAR-T therapy. OR
• Any therapy that is targeting STEAP2.
• Active or prior documented autoimmune or inflammatory disorders
• Cardiac arrhythmias which are symptomatic or require treatment unless controlled by pacemaker (judged by investigator); symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
• Active infection, including:
• HBV infection is defined as hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and HBV DNA detectable.
• HCV infection is defined as HCV antibody positive and HCV RNA positive.
• CMV infection is defined as CMV DNA detectable.
• Syphilis infection is defined as syphilis antigen and antibody positive.
• HIV infection is defined as HIV 1/2 antibody positive.
• Other persistent or active infections requiring systemic treatment (prophylactic use of anti-infective drugs is allowed).
• Patients with central nervous system (CNS) diseases:
• Obvious risk or tendency of bleeding or active bleeding (eg, clinically significant hemoptysis, tumour bleeding, history of von Willebrand disease or hemophilia etc.).
• Plans to father a child during the study period.
• Patients with alcohol or drug abuse.
• Participants may not receive full-dose long acting oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the time of informed consent to 28 days post infusion of A-CAR032. Use of short acting direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Tongji Hospital, Tongji Medical College of HUST — Wuhan, Hubei, China (enrolling)
• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China (enrolling)
• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
• Beijing GoBroad Hospital — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.